Acurx Pharmaceuticals, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Joseph C Scodari. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Joseph C Scodari has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ACXP / Acurx Pharmaceuticals, Inc. Director 27,708
US:OPTN / OptiNose, Inc. Director 14,439
US:CVD / Covance, Inc. Director 0
Director 6,515
US:JNJ / Johnson & Johnson Executive Committee Member 5,390
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Joseph C Scodari. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ACXP / Acurx Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACXP / Acurx Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2025-01-06 ACXP Scodari Joseph C 24,631 1.0150 1,232 20.3000 25,000 231 5.3500 -18,414 -73.66

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACXP / Acurx Pharmaceuticals, Inc. Insider Trades
Insider Sales ACXP / Acurx Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACXP / Acurx Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACXP / Acurx Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Joseph C Scodari as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-01-08 2025-01-06 4 ACXP Acurx Pharmaceuticals, Inc.
Common Stock
P - Purchase 24,631 27,708 800.49 1.02 25,000 28,124
2021-07-06 2021-07-01 4 ACXP Acurx Pharmaceuticals, Inc.
Stock Option
A - Award 50,000 50,000
2021-06-24 3 ACXP Acurx Pharmaceuticals, Inc.
Common Stock
3,077
2021-06-10 2021-06-09 4 OPTN OptiNose, Inc.
Stock Option (Right to Buy)
A - Award 14,439 14,439
2021-05-11 2021-05-10 4 OPTN OptiNose, Inc.
Common Stock
P - Purchase 10,000 31,230 47.10 2.99 29,900 93,378
2020-06-12 2020-06-10 4 OPTN OptiNose, Inc.
Stock Option (Right to Buy)
A - Award 14,439 28,878 100.00 5.65 81,580 163,161
2020-03-09 2020-03-06 4 OPTN OptiNose, Inc.
Common Stock
P - Purchase 200 21,230 0.95 5.52 1,105 117,296
2020-03-09 2020-03-06 4 OPTN OptiNose, Inc.
Common Stock
P - Purchase 2,000 21,030 10.51 5.56 11,125 116,975
2020-03-09 2020-03-06 4 OPTN OptiNose, Inc.
Common Stock
P - Purchase 6,500 19,030 51.88 5.75 37,375 109,422
2019-12-09 2019-12-06 4 OPTN OptiNose, Inc.
Common Stock
P - Purchase 6,100 12,530 94.87 8.22 50,142 102,997
2019-06-10 2019-06-06 4 OPTN OptiNose, Inc.
Stock Option (Right to Buy)
A - Award 14,439 14,439 6.60 95,297 95,297
2018-12-12 2018-12-12 4 OPTN OptiNose, Inc.
Common Stock
P - Purchase 6,430 6,430 7.89 50,733 50,733
2018-06-11 2018-06-11 4 OPTN OptiNose, Inc.
Stock Option (Right to Buy)
A - Award 14,439 14,439 22.50 324,878 324,878
2017-10-16 2017-10-12 4 OPTN OptiNose, Inc.
Stock Option (Right to Buy)
A - Award 43,318 43,318
2015-02-23 2015-02-19 4 CVD COVANCE INC
Directors Stock Option Plan
D - Sale to Issuer -2,800 0 -100.00
2015-02-23 2015-02-19 4 CVD COVANCE INC
Directors Stock Option Plan
D - Sale to Issuer -2,800 0 -100.00
2015-02-23 2015-02-19 4 CVD COVANCE INC
Directors Stock Option Plan
D - Sale to Issuer -2,800 0 -100.00
2015-02-23 2015-02-19 4 CVD COVANCE INC
Directors Stock Option Plan
D - Sale to Issuer -1,700 0 -100.00
2015-02-23 2015-02-19 4 CVD COVANCE INC
Common Stock
D - Sale to Issuer -7,466 0 -100.00
2014-05-22 2014-05-20 4 CVD COVANCE INC
Phantom Stock Units (DRUP) - 2011 Award
M - Exercise -1,505 0 -100.00
2014-05-22 2014-05-20 4 CVD COVANCE INC
Common Stock
D - Sale to Issuer -1,505 7,466 -16.78 83.78 -126,083 625,472
2014-05-22 2014-05-20 4 CVD COVANCE INC
Common Stock
M - Exercise 1,505 8,971 20.16
2014-05-08 2014-05-06 4 CVD COVANCE INC
Common Stock
A - Award 2,426 7,466 48.13
2013-05-22 2013-05-20 4 CVD COVANCE INC
Phantom Stock Units (DRUP) - 2010 Award
M - Exercise -1,600 0 -100.00
2013-05-22 2013-05-20 4 CVD COVANCE INC
Common Stock
D - Sale to Issuer -1,600 5,040 -24.10 75.96 -121,538 382,843
2013-05-22 2013-05-20 4 CVD COVANCE INC
Common Stock
M - Exercise 1,600 6,640 31.75
2013-05-09 2013-05-07 4 CVD COVANCE INC
Common Stock
A - Award 1,367 5,040 37.22
2013-03-14 2013-03-12 4 ENDP ENDO HEALTH SOLUTIONS INC.
2010 Stock Incentive Plan Restricted Stock Units (RSU)
A - Award 6,515 6,515
2013-01-03 2012-12-31 4 ENDP ENDO HEALTH SOLUTIONS INC.
Common Stock, par value, $.01 per share
A - Award 1,258 32,102 4.08
2012-10-02 2012-09-28 4 ENDP ENDO HEALTH SOLUTIONS INC.
Common Stock, par value, $.01 per share
A - Award 993 30,844 3.33
2012-07-03 2012-06-29 4 ENDP ENDO HEALTH SOLUTIONS INC.
Common Stock, par value, $.01 per share
A - Award 1,041 29,851 3.61
2012-05-22 2012-05-21 4 CVD COVANCE INC
Phantom Stock Units (DRUP) - 2009 Award
M - Exercise -2,000 0 -100.00
2012-05-22 2012-05-21 4 CVD COVANCE INC
Common Stock
D - Sale to Issuer -2,000 3,673 -35.25 45.39 -90,780 166,717
2012-05-22 2012-05-21 4 CVD COVANCE INC
Common Stock
M - Exercise 2,000 5,673 54.45
2012-05-22 2012-05-21 4 CVD COVANCE INC
Phantom Stock Units (DRUP) - 2009 Award
M - Exercise -2,000 0 -100.00
2012-05-22 2012-05-21 4 CVD COVANCE INC
Common Stock
D - Sale to Issuer -2,000 3,673 -35.25 45.39 -90,780 166,717
2012-05-22 2012-05-21 4 CVD COVANCE INC
Common Stock
M - Exercise 2,000 5,673 54.45
2012-05-10 2012-05-08 4 CVD COVANCE INC
Common Stock
A - Award 2,173 3,673 144.87
2012-04-03 2012-03-30 4 ENDP ENDO PHARMACEUTICALS HOLDINGS INC
Common Stock, par value, $.01 per share
A - Award 775 28,810 2.76
2012-03-14 2012-03-12 4 ENDP ENDO PHARMACEUTICALS HOLDINGS INC
2007 Stock Incentive Plan Restricted Stock Units (RSU)
M - Exercise -1,417 0 -100.00
2012-03-14 2012-03-12 4 ENDP ENDO PHARMACEUTICALS HOLDINGS INC
Common Stock, par value, $.01 per share
M - Exercise 1,417 28,035 5.32
2012-03-14 2012-03-12 4 ENDP ENDO PHARMACEUTICALS HOLDINGS INC
2010 Stock Incentive Plan Restricted Stock Units (RSU)
A - Award 5,481 5,481
2012-01-03 2011-12-30 4 ENDP ENDO PHARMACEUTICALS HOLDINGS INC
Common Stock, par value, $.01 per share
A - Award 695 22,554 3.18
2005-03-10 3 JNJ JOHNSON & JOHNSON
Common
5,390
2005-03-10 3 JNJ JOHNSON & JOHNSON
Common
2,239
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)